Friday, July 10, 2026

Drug profile · INN

flurbiprofen sodium

flurbiprofen sodium (OCUFEN) is a cyclooxygenase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — flurbiprofen sodium
US status
approved
Class
Route
OPHTHALMIC
Patents
0
Programs
0
Data quality
0.84

Quick answer

flurbiprofen sodium (OCUFEN) is a cyclooxygenase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.

Key facts

INN flurbiprofen sodium
Brand OCUFEN
Mechanism Cyclooxygenase inhibitor
Target Cyclooxygenase
Route OPHTHALMIC
Formulation SOLUTION/DROPS

Mechanism of action

Cyclooxygenase inhibitor

Primary target: Cyclooxygenase

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. aspirin Cyclooxygenase inhibitor
  2. bromfenac sodium Cyclooxygenase inhibitor
  3. diclofenac potassium Cyclooxygenase inhibitor
  4. diclofenac sodium Cyclooxygenase inhibitor
  5. diflunisal Nervous system (N02)
  6. fenoprofen calcium Cyclooxygenase inhibitor

Frequently asked questions

What is flurbiprofen sodium?

flurbiprofen sodium (OCUFEN) is a cyclooxygenase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.

What is the brand name for flurbiprofen sodium?

OCUFEN is a marketed brand name for flurbiprofen sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of flurbiprofen sodium?

flurbiprofen sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.